|
||
J. Exp. Med.,
Volume 189, Number 6, March 15, 1999 1005-1010
By

¶
From the * DNAX Research Institute of Molecular and Cellular Biology, Inc., Palo Alto, California
94304; The effectiveness of interleukin 10 (IL-10) in the treatment of autoimmune-mediated central
nervous system inflammation is controversial. Studies of the model system, experimental autoimmune encephalomyelitis (EAE), using various routes, regimens, and delivery methods of
IL-10 suggest that these variables may affect its immunoregulatory function. To study the influence of these factors on IL-10 regulation of EAE pathogenesis, we have analyzed transgenic
mice expressing human IL-10 (hIL-10) transgene under the control of a class II major histocompatibility complex (MHC) promoter. The hIL-10 transgenic mice are highly resistant to
EAE induced by active immunization, and this resistance appears to be mediated by suppression of autoreactive T cell function. Myelin-reactive T helper 1 cells are induced but nonpathogenic in the IL-10 transgenic mice. Antibody depletion confirmed that EAE resistance is
dependent on the presence of the transgenic IL-10. Mice expressing the hIL-10 transgene
but not the endogenous murine IL-10 gene demonstrated that transgenic IL-10 from MHC
class II-expressing cells is sufficient to block induction of EAE. This study demonstrates that
IL-10 can prevent EAE completely if present at appropriate levels and times during disease induction.
Institut National de la Santé et de la Recherche Médicale, U343 Hopital de I'Archet,
06200 Nice, France; and the Department of § Molecular Microbiology and Immunology,
the
Department of Pathology, and the ¶ Department of Neurology, University of Southern California
at Los Angeles School of Medicine, Los Angeles, California 90033
This article has been cited by other articles:
| TABLE OF CONTENTS |
|